相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial
Z. Punthakee et al.
DIABETOLOGIA (2012)
Macrovascular Effects and Safety Issues of Therapies for Type 2 Diabetes
Jorge Plutzky
AMERICAN JOURNAL OF CARDIOLOGY (2011)
Peroxisome Proliferator-Activated Receptor-α Activation Promotes Macrophage Reverse Cholesterol Transport Through a Liver X Receptor-Dependent Pathway
Kazuhiro Nakaya et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Prevention of Overweight/Obesity as a Strategy to Optimize Cardiovascular Health
Marc-Andre Cornier et al.
CIRCULATION (2011)
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone Interim report of a longitudinal cohort study
James D. Lewis et al.
DIABETES CARE (2011)
Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients Insights From the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) Study
Stephen J. Nicholls et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Effect of Synthetic Ligands of PPAR α, β/δ, γ, RAR, RXR and LXR on the Fatty Acid Composition of Phospholipids in Mice
Kathrin Weiss et al.
LIPIDS (2011)
Therapeutic Potential of Aleglitazar, a New Dual PPAR-alpha/gamma Agonist Implications for Cardiovascular Disease in Patients with Diabetes Mellitus
Matthew A. Cavender et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2010)
Rosiglitazone Revisited An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality
Steven E. Nissen et al.
ARCHIVES OF INTERNAL MEDICINE (2010)
The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans
Ashish Shah et al.
ATHEROSCLEROSIS (2010)
Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
Hertzel C. Gerstein et al.
CIRCULATION (2010)
Cardiovascular Disease in Diabetes
Z. T. Bloomgarden
DIABETES CARE (2010)
The effects of rosiglitazone on atherosclerotic progression in patients with Type 2 diabetes at high cardiovascular risk
M. S. Yee et al.
DIABETIC MEDICINE (2010)
Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes
Koji Nakano et al.
ENDOCRINE JOURNAL (2010)
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Min Jun et al.
LANCET (2010)
PPARα: an emerging therapeutic target in diabetic microvascular damage
Anne Hiukka et al.
NATURE REVIEWS ENDOCRINOLOGY (2010)
The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus.
Lukasz Januszkiewicz
KARDIOLOGIA POLSKA (2010)
PPAR-γ Activation As an Anti-inflammatory Therapy for Respiratory Virus Infections
Josep Bassaganya-Riera et al.
VIRAL IMMUNOLOGY (2010)
Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver
Alexandra Rogue et al.
PPAR RESEARCH (2010)
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Henry N. Ginsberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Potent and Selective PPAR-alpha Agonist LY518674 Upregulates Both ApoA-I Production and Catabolism in Human Subjects With the Metabolic Syndrome
John S. Millar et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate
Marja-Riitta Taskinen et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the Vein-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial
Olivier F. Bertrand et al.
CANADIAN JOURNAL OF CARDIOLOGY (2009)
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Yoon K. Loke et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes An Overview of Data from PROactive
John Dormandy et al.
DRUG SAFETY (2009)
Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in People With Impaired Glucose Tolerance or Impaired Fasting Glucose STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone)
Eva M. Lonn et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
The Pathologic Continuum of Diabetic Vascular Disease
Gabriela Orasanu et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study
Robert R. Henry et al.
LANCET (2009)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Philip D. Home et al.
LANCET (2009)
Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10)
Robert Wilcox et al.
AMERICAN HEART JOURNAL (2008)
PPARδ/β:: The lobbyist switching macrophage allegiance in favor of metabolism
Beatrice Desvergne
CELL METABOLISM (2008)
Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus
Michael Davidson et al.
CIRCULATION (2008)
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes -: The PERISCOPE randomized controlled trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia
Jean-Charles Hogue et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2008)
Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies
Mark A. Deeg et al.
PPAR RESEARCH (2008)
Lipids, lipoproteins, and peroxisome proliferator activated receptor-δ
Dennis L. Sprecher
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials
Rodrigo M. Lago et al.
LANCET (2007)
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus - A meta-analysis of randomized trials
A. Michael Lincoff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis
Philip D. Home et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes
M. Rizzo et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes - A randomized trial
Theodore Mazzone et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (α/γ) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy
DM Kendall et al.
DIABETES CARE (2006)
Gemfibrozil in the treatment of dyslipidemia -: An 18-year mortality follow-up of the Helsinki Heart Study
L Tenkanen et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency
IL Ruel et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus
SE Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial
A Keech et al.
LANCET (2005)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner
R Arakawa et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome
A Tenenbaum et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Novel Approach to Treat Insulin Resistance, Type 2 Diabetes, and the Metabolic Syndrome: Simultaneous Activation of PPAR alpha, PPAR gamma, and PPAR delta
Joseph L. Evans et al.
CURRENT DIABETES REVIEWS (2005)
Peroxisome proliferator-activated receptor-alpha and atherosclerosis: From basic mechanisms to clinical implications
Z Israelian-Konaraki et al.
CARDIOLOGY (2005)
Drug therapy: Thiazolidinediones
H Yki-Jarvinen
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions
CB Renard et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Combined thiazolidinedione-insulin therapy - Should we be concerned about safety?
AJ Scheen
DRUG SAFETY (2004)
Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia
S Bilz et al.
JOURNAL OF LIPID RESEARCH (2004)
Thiazolidinedione use, fluid retention, and congestive heart failure
RW Nesto et al.
DIABETES CARE (2004)
Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus
JS Sidhu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Antidiabetic PPARγ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease
N Marx et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance
WT Garvey et al.
DIABETES (2003)
Diabetes, plasma insulin, and cardiovascular disease - Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT)
HB Rubins et al.
ARCHIVES OF INTERNAL MEDICINE (2002)
AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update - Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases
TA Pearson et al.
CIRCULATION (2002)
Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes
Y Miyazaki et al.
DIABETES CARE (2002)
Relation of gemfibrozil treatment and lipid levels with major coronary events - VA-HIT: A randomized controlled trial
SJ Robins et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
G Chinetti et al.
NATURE MEDICINE (2001)
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers
S Mudaliar et al.
ANNUAL REVIEW OF MEDICINE (2001)
分享论文
